thalidomide has been researched along with Constipation in 37 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 9.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "To determine the efficacy of thalidomide in suppressing cough in patients with IPF." | 9.16 | Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. ( Danoff, SK; Horton, KM; Horton, MR; Lechtzin, N; Liu, MC; Mathew, L; Polito, AJ; Santopietro, V, 2012) |
| "Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. ( Ch'ang, HJ; Chang, JS; Chang, YH; Chen, CH; Chen, LT; Hsu, C, 2012) |
| "To investigate the efficacy and toxicity of bortezomib based combination therapy for Chinese patients with relapsed or refractory multiple myeloma (MM), and to determine the combination regimen, dosage and cycles in application of bortezomib for MM therapy." | 9.13 | [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2008) |
| "Thalidomide is effective in treating refractory and relapsed multiple myeloma (MM)." | 9.12 | [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2007) |
| "Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities." | 9.11 | Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004) |
| " Bisphosphonates combined with thalidomide, a drug possessing confirmed anti-myeloma activity, seem to have potential favorable effect in patients with treatment-resistant multiple myeloma with advanced osteolytic lesions." | 9.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas." | 9.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 9.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 9.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%." | 8.84 | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008) |
| "Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM)." | 8.84 | Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. ( Tariman, JD, 2007) |
| "Thalidomide is highly effective against multiple myeloma, but some patients must discontinue this medication due to adverse effects." | 7.81 | [Thalidomide-associated hypothyroidism in a patient with multiple myeloma]. ( Ikeda, T; Kimura, F; Okamura, I; Sato, K, 2015) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | 7.76 | [Factors affecting the response of thalidomide therapy for patients with multiple myeloma]. ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 7.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM)." | 7.71 | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. ( Grover, JK; Raina, V; Uppal, G, 2002) |
| "To observe the effective mechanism and side effects of thalidomide to multiple myeloma (MM)." | 7.71 | [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism]. ( Li, Y; Liu, Y; Wang, M; Wu, H, 2002) |
| "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA." | 7.71 | Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002) |
| "Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF." | 6.71 | [Single-agent thalidomide for advanced and refractory multiple myeloma]. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2003) |
| "Thalidomide was well tolerated: the most common side effects were constipation (76." | 6.71 | Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. ( Carillio, G; Fanelli, M; Gasparini, G; Gattuso, D; Morabito, A; Sarmiento, R, 2004) |
| "The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians." | 6.41 | Thalidomide in myelodysplastic syndromes. ( Pozzato, G; Zorat, F, 2002) |
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 5.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. ( Ch'ang, HJ; Chang, JS; Chang, YH; Chen, CH; Chen, LT; Hsu, C, 2012) |
| "To determine the efficacy of thalidomide in suppressing cough in patients with IPF." | 5.16 | Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. ( Danoff, SK; Horton, KM; Horton, MR; Lechtzin, N; Liu, MC; Mathew, L; Polito, AJ; Santopietro, V, 2012) |
| "We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM)." | 5.14 | Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. ( Detweiler-Short, K; Dispenzieri, A; Gertz, MA; Greipp, PR; Hayman, S; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Russell, SJ; Vincent Rajkumar, S; Witzig, TE; Zeldenrust, SR, 2010) |
| "To investigate the efficacy and toxicity of bortezomib based combination therapy for Chinese patients with relapsed or refractory multiple myeloma (MM), and to determine the combination regimen, dosage and cycles in application of bortezomib for MM therapy." | 5.13 | [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2008) |
| "Thalidomide is effective in treating refractory and relapsed multiple myeloma (MM)." | 5.12 | [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma]. ( Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG, 2007) |
| "Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities." | 5.11 | Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004) |
| " We report the final results of a phase II trial of thalidomide as initial therapy for early-stage multiple myeloma in an attempt to delay progression to symptomatic disease." | 5.10 | Thalidomide as initial therapy for early-stage myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Iturria, N; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy." | 5.10 | Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. ( Anderson, KC; Balinski, K; Catley, LP; Chauhan, D; Davies, F; Deocampo, R; Doss, D; Freeman, A; Hideshima, T; Kelly, K; LeBlanc, R; McKenney, M; Mechlowicz, J; Mitsiades, C; Rich, R; Richardson, PG; Ryoo, JJ; Schlossman, RL; Weller, E; Zeldis, J, 2002) |
| "We conclude that the combination of thalidomide plus dexamethasone is a feasible and active regimen in the treatment of multiple myeloma." | 5.10 | Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, S; Iturria, N; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2002) |
| " Bisphosphonates combined with thalidomide, a drug possessing confirmed anti-myeloma activity, seem to have potential favorable effect in patients with treatment-resistant multiple myeloma with advanced osteolytic lesions." | 5.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas." | 5.09 | Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. ( Black, PM; Figg, WD; Fine, HA; Jaeckle, K; Kaplan, R; Kyritsis, AP; Levin, VA; Loeffler, JS; Pluda, JM; Wen, PY; Yung, WK, 2000) |
| "The aim of this study was to define prognostic factors that might be predictive for response to thalidomide (Thal) in progressive multiple myeloma (n = 54)." | 5.09 | High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Hillengass, J; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2001) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 5.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma." | 4.86 | Palliative oncology: thalidomide. ( Prommer, EE, 2010) |
| "Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM)." | 4.84 | Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. ( Tariman, JD, 2007) |
| "Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%." | 4.84 | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008) |
| "Thalidomide is highly effective against multiple myeloma, but some patients must discontinue this medication due to adverse effects." | 3.81 | [Thalidomide-associated hypothyroidism in a patient with multiple myeloma]. ( Ikeda, T; Kimura, F; Okamura, I; Sato, K, 2015) |
| "Factors that affect the response of multiple myeloma patients to thalidomide were evaluated in 40 patients who were not eligible for chemotherapy (untreated: 14, relapse/refractory: 26)." | 3.76 | [Factors affecting the response of thalidomide therapy for patients with multiple myeloma]. ( Agata, M; Ishiyama, M; Kazama, H; Kondo, T; Mori, N; Motoji, T; Oda, T; Okamura, T; Sagawa, K; Sameshima, Y; Shiseki, M; Teramura, M; Yamada, O; Yasunami, T; Yoshinaga, K, 2010) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 3.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "To observe the effective mechanism and side effects of thalidomide to multiple myeloma (MM)." | 3.71 | [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism]. ( Li, Y; Liu, Y; Wang, M; Wu, H, 2002) |
| "Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM)." | 3.71 | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. ( Grover, JK; Raina, V; Uppal, G, 2002) |
| "We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA." | 3.71 | Thalidomide for the treatment of patients with myelodysplastic syndromes. ( Aivado, M; Gattermann, N; Germing, U; Haas, R; Misgeld, E; Strupp, C, 2002) |
| "Oral lenalidomide 25 mg was self-administered once daily on days 1 to 21 of every 28-day cycle for up to 52 weeks as tolerated, or until disease progression." | 2.74 | Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. ( Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB, 2009) |
| "Disease progression was observed in 14 (45%) patients." | 2.73 | Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. ( Amato, RJ; Malya, R; Rawat, A, 2008) |
| "Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF." | 2.71 | [Single-agent thalidomide for advanced and refractory multiple myeloma]. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2003) |
| "Thalidomide was well tolerated: the most common side effects were constipation (76." | 2.71 | Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. ( Carillio, G; Fanelli, M; Gasparini, G; Gattuso, D; Morabito, A; Sarmiento, R, 2004) |
| " The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear." | 2.70 | A phase II study of thalidomide in advanced metastatic renal cell carcinoma. ( Damico, LA; Elias, L; Meng, G; Minor, DR; Monroe, D; Suryadevara, U, 2002) |
| "Treatment continued until disease progression or unacceptable toxicity were encountered." | 2.70 | The treatment of advanced renal cell cancer with high-dose oral thalidomide. ( Ahern, R; Benson, C; Bridle, H; Eisen, T; Gore, ME; Mak, I; Pyle, L; Sapunar, F; Smalley, K; Stebbing, J, 2001) |
| "The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians." | 2.41 | Thalidomide in myelodysplastic syndromes. ( Pozzato, G; Zorat, F, 2002) |
| "Four patients died due to disease progression and 17 were found to have progressed after ASCT (the median progression-free survival after ASCT was 19." | 1.40 | Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. ( Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.70) | 18.2507 |
| 2000's | 26 (70.27) | 29.6817 |
| 2010's | 10 (27.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, WJ | 1 |
| Kang, ES | 1 |
| Lee, ST | 1 |
| Kim, SH | 1 |
| Kim, DW | 1 |
| Kim, SJ | 1 |
| Kim, K | 1 |
| Okamura, I | 1 |
| Ikeda, T | 1 |
| Sato, K | 1 |
| Kimura, F | 1 |
| Wang, D | 1 |
| Chen, H | 1 |
| Wang, S | 1 |
| Zou, Y | 1 |
| Li, J | 1 |
| Pan, J | 1 |
| Wang, X | 1 |
| Ren, T | 1 |
| Zhang, Y | 1 |
| Chen, Z | 1 |
| Feng, X | 1 |
| Sun, L | 1 |
| Popat, R | 1 |
| Brown, SR | 1 |
| Flanagan, L | 1 |
| Hall, A | 1 |
| Gregory, W | 1 |
| Kishore, B | 1 |
| Streetly, M | 1 |
| Oakervee, H | 1 |
| Yong, K | 1 |
| Cook, G | 2 |
| Low, E | 1 |
| Cavenagh, J | 1 |
| Amato, RJ | 1 |
| Malya, R | 1 |
| Rawat, A | 1 |
| von Lilienfeld-Toal, M | 1 |
| Hahn-Ast, C | 1 |
| Furkert, K | 1 |
| Hoffmann, F | 1 |
| Naumann, R | 1 |
| Bargou, R | 1 |
| Glasmacher, A | 1 |
| Yuan, ZG | 2 |
| Hou, J | 2 |
| Wang, DX | 2 |
| Fu, WJ | 2 |
| Chen, YB | 2 |
| Xi, H | 2 |
| Witzig, TE | 5 |
| Wiernik, PH | 1 |
| Moore, T | 1 |
| Reeder, C | 1 |
| Cole, C | 1 |
| Justice, G | 1 |
| Kaplan, H | 1 |
| Voralia, M | 1 |
| Pietronigro, D | 1 |
| Takeshita, K | 1 |
| Ervin-Haynes, A | 1 |
| Zeldis, JB | 1 |
| Vose, JM | 1 |
| Prommer, EE | 1 |
| Agata, M | 1 |
| Sameshima, Y | 1 |
| Oda, T | 1 |
| Kondo, T | 1 |
| Ishiyama, M | 1 |
| Yasunami, T | 1 |
| Kazama, H | 1 |
| Okamura, T | 1 |
| Yoshinaga, K | 1 |
| Shiseki, M | 1 |
| Mori, N | 1 |
| Yamada, O | 1 |
| Sagawa, K | 1 |
| Teramura, M | 1 |
| Motoji, T | 1 |
| Detweiler-Short, K | 1 |
| Hayman, S | 3 |
| Gertz, MA | 4 |
| Lacy, MQ | 4 |
| Dispenzieri, A | 4 |
| Kumar, S | 2 |
| Zeldenrust, SR | 1 |
| Russell, SJ | 1 |
| Lust, JA | 4 |
| Kyle, RA | 4 |
| Greipp, PR | 4 |
| Vincent Rajkumar, S | 1 |
| Ch'ang, HJ | 1 |
| Hsu, C | 1 |
| Chen, CH | 1 |
| Chang, YH | 1 |
| Chang, JS | 1 |
| Chen, LT | 1 |
| Horton, MR | 1 |
| Santopietro, V | 1 |
| Mathew, L | 1 |
| Horton, KM | 1 |
| Polito, AJ | 1 |
| Liu, MC | 1 |
| Danoff, SK | 1 |
| Lechtzin, N | 1 |
| Grover, JK | 1 |
| Uppal, G | 1 |
| Raina, V | 1 |
| Richardson, PG | 1 |
| Schlossman, RL | 1 |
| Weller, E | 1 |
| Hideshima, T | 1 |
| Mitsiades, C | 1 |
| Davies, F | 1 |
| LeBlanc, R | 1 |
| Catley, LP | 1 |
| Doss, D | 1 |
| Kelly, K | 1 |
| McKenney, M | 1 |
| Mechlowicz, J | 1 |
| Freeman, A | 1 |
| Deocampo, R | 1 |
| Rich, R | 1 |
| Ryoo, JJ | 1 |
| Chauhan, D | 1 |
| Balinski, K | 1 |
| Zeldis, J | 1 |
| Anderson, KC | 1 |
| Rajkumar, SV | 3 |
| Geyer, S | 1 |
| Iturria, N | 2 |
| Fonseca, R | 3 |
| Minor, DR | 1 |
| Monroe, D | 1 |
| Damico, LA | 1 |
| Meng, G | 1 |
| Suryadevara, U | 1 |
| Elias, L | 1 |
| Wang, M | 1 |
| Liu, Y | 1 |
| Li, Y | 1 |
| Wu, H | 1 |
| Geyer, SM | 1 |
| Okikawa, Y | 1 |
| Takimoto, Y | 1 |
| Noda, M | 1 |
| Imagawa, J | 1 |
| Katayama, Y | 1 |
| Sakai, A | 1 |
| Okita, H | 1 |
| Fujimura, K | 1 |
| Kimura, A | 1 |
| Morabito, A | 1 |
| Fanelli, M | 1 |
| Carillio, G | 1 |
| Gattuso, D | 1 |
| Sarmiento, R | 1 |
| Gasparini, G | 1 |
| Offidani, M | 1 |
| Corvatta, L | 1 |
| Marconi, M | 1 |
| Malerba, L | 1 |
| Mele, A | 1 |
| Olivieri, A | 1 |
| Brunori, M | 1 |
| Catarini, M | 1 |
| Candela, M | 1 |
| Capelli, D | 1 |
| Montanari, M | 1 |
| Rupoli, S | 1 |
| Leoni, P | 1 |
| Dimopoulos, MA | 1 |
| Eleutherakis-Papaiakovou, V | 1 |
| Dingli, D | 1 |
| Nowakowski, GS | 1 |
| Ueki, T | 1 |
| Ohashi, K | 1 |
| Matsumoto, H | 1 |
| Nakajima, H | 1 |
| Akiyama, H | 1 |
| Sakamaki, H | 1 |
| Tariman, JD | 1 |
| Parker, PM | 1 |
| Chao, N | 1 |
| Nademanee, A | 1 |
| O'Donnell, MR | 1 |
| Schmidt, GM | 1 |
| Snyder, DS | 1 |
| Stein, AS | 1 |
| Smith, EP | 1 |
| Molina, A | 1 |
| Stepan, DE | 1 |
| Kashyap, A | 1 |
| Planas, I | 1 |
| Spielberger, R | 1 |
| Somlo, G | 1 |
| Margolin, K | 1 |
| Zwingenberger, K | 1 |
| Wilsman, K | 1 |
| Negrin, RS | 1 |
| Long, GD | 1 |
| Niland, JC | 1 |
| Blume, KG | 1 |
| Forman, SJ | 1 |
| Fine, HA | 1 |
| Figg, WD | 1 |
| Jaeckle, K | 1 |
| Wen, PY | 1 |
| Kyritsis, AP | 1 |
| Loeffler, JS | 1 |
| Levin, VA | 1 |
| Black, PM | 1 |
| Kaplan, R | 1 |
| Pluda, JM | 1 |
| Yung, WK | 1 |
| Kyriakis, KP | 1 |
| Kontochristopoulos, GJ | 1 |
| Panteleos, DN | 1 |
| Neben, K | 1 |
| Moehler, T | 1 |
| Egerer, G | 1 |
| Kraemer, A | 1 |
| Hillengass, J | 1 |
| Benner, A | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Stebbing, J | 1 |
| Benson, C | 1 |
| Eisen, T | 1 |
| Pyle, L | 1 |
| Smalley, K | 1 |
| Bridle, H | 1 |
| Mak, I | 1 |
| Sapunar, F | 1 |
| Ahern, R | 1 |
| Gore, ME | 1 |
| Strupp, C | 1 |
| Germing, U | 1 |
| Aivado, M | 1 |
| Misgeld, E | 1 |
| Haas, R | 1 |
| Gattermann, N | 1 |
| Zorat, F | 1 |
| Pozzato, G | 1 |
| Ciepłuch, H | 1 |
| Baran, W | 1 |
| Hellmann, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715] | Phase 1/Phase 2 | 54 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
| A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma[NCT00179673] | Phase 2 | 43 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Pilot Clinical and Mechanistic Study of Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma[NCT00155272] | Phase 1/Phase 2 | 19 participants | Interventional | 2005-03-31 | Recruiting | ||
| Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide[NCT00600028] | Phase 3 | 25 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients[NCT00396045] | Phase 1/Phase 2 | 54 participants | Interventional | 2005-01-31 | Completed | ||
| A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332] | Phase 2 | 12 participants (Actual) | Interventional | 2016-12-12 | Terminated (stopped due to FDA Hold Due to Updated Risks) | ||
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma[NCT00263484] | Phase 2 | 56 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad[NCT00443235] | Phase 3 | 260 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas[NCT00047879] | Phase 2 | 7 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Response was defined as participants with a complete response (CR), unconfirmed complete response (Cru) or partial response (PR), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator. CR: Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities.~Cru: Criteria for CR above but with 1 or more of the following:~A residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of diameters (SPD)~Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia).~PR: ≥ 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD." (NCT00179673)
Timeframe: From enrollment through study completion. Median duration on study was 4.4 months with a maximum of 32 months
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 23.3 |
"Tumor control was defined as participants with a complete response, unconfirmed complete response, partial response or stable disease (SD), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator.~SD was defined as a response less than a PR (see above) but not Progressive Disease (PD).~PD was defined as~≥ 50 % increase from nadir in the SPD of any previously identified abnormal node for partial responders or non-responders.~Appearance of any new lesion during or at the end of therapy." (NCT00179673)
Timeframe: From enrollment through study completion. Median duration on study was 4.4 months with a maximum of 32 months
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 60.5 |
Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first. Participants who withdrew for any reason or received another NHL therapy including stem cell transplantation without documented progressive disease were censored on the date of their last adequate response assessment indicating no progression (or last adequate assessment prior to receiving other NHL therapy). Participants who were still active without progressive disease at the time of the data cut-off date were censored on the date of their last adequate response assessment. (NCT00179673)
Timeframe: From enrollment through study completion. Median duration on study was 4.4 months with a maximum of 32 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 4.4 |
The duration of response was calculated as the first response assessment demonstrating evidence of at least a partial response to the first documentation of progressive disease (as determined by computed tomography scan) or death due to NHL, whichever occurred first. For participants without documentation of progression, the duration of response was censored at the last date of tumor assessment indicating no progression. Median was based on the Kaplan-Meier estimate. (NCT00179673)
Timeframe: From enrollment through study completion. Median duration on study was 4.4 months with a maximum of 32 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | NA |
"The Investigator determined the relationship between the administration of study drug and the occurrence of an AE as suspected if the temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other drugs, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event.~The Investigator graded the severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria and the following scale:~Grade 1 = Mild~Grade 2 = Moderate~Grade 3 = Severe~Grade 4 = Life threatening~Grade 5 = Death~A Serious AE is defined as any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event." (NCT00179673)
Timeframe: From the start of study drug through 30 days after the last dose of study drug. Maximum time on study drug was 13.8 months.
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| At least one Adverse Event (AE) | ≥ 1 AE related to study drug | Grade (GR) 3-5 AE | Grade 3-5 AE related to study drug | Serious adverse event (SAE) | SAE related to study drug | AE leading to discontinuation of study drug | Related AE leading to study drug discontinuation | AE leading to dose reduction or interruption | |
| Lenalidomide | 42 | 37 | 27 | 24 | 18 | 10 | 9 | 5 | 27 |
"The primary endpoint, suppression of cough was measured by the Cough Quality of Life Questionnaire (CQLQ) to measure the effect of interventions on cough-specific quality of life.~CQLQ consist of 28 questions about cough and its effects using Likert-like 4-point scales, with lower scores indicating less effect of cough on health related quality of life.~CQLQ scale ranges from 28 to 112 ( The lower the value, the higher the quality of life, 28 is considered the best)." (NCT00600028)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide) | 47.3 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo) | 55.2 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo) | 61.6 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide) | 44.5 |
"The secondary endpoint, suppression of cough was measured by the visual analog scale of cough (VAS) was significantly lower during treatment with thalidomide than placebo.~Secondary endpoints were Cough VAS - the visual analog scale of cough evaluates the severity of cough in patients with IPF.~Visual analog scale of cough ranges from 0 to 100 (0 is considered the best).~St. George Respiratory Questionnaire helps to evaluate cough-specific and respiratory quality of life in patients with IPF.~St. George Respiratory Questionnaire score ranges from 0 to 100 (0 is considered the best)." (NCT00600028)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Severity of cough (VAS Score) | Quality of life (SGRQ Score) | |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo) | 68 | 58.8 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide) | 17.8 | 40.7 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo) | 65.9 | 54.7 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide) | 30.3 | 46.4 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 11 |
Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 1 |
Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 10 |
PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Lenalidomide | 27.6 |
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00047879)
Timeframe: 4 months
| Intervention | Participants (Number) |
|---|---|
| Glioblastoma Multiforme Stratum | 4 |
| Anaplastic Glioma Stratum | 2 |
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
5 reviews available for thalidomide and Constipation
| Article | Year |
|---|---|
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Constipation; De | 2008 |
Palliative oncology: thalidomide.
Topics: Angiogenesis Inhibitors; Constipation; Cytokines; Drug Eruptions; Humans; Hydrolysis; Hypotension, O | 2010 |
Adverse effects of thalidomide administration in patients with neoplastic diseases.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials, Phase II | 2004 |
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; | 2007 |
Thalidomide in myelodysplastic syndromes.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Chromosome Abe | 2002 |
21 trials available for thalidomide and Constipation
| Article | Year |
|---|---|
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Constipation; Di | 2008 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2008 |
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; | 2009 |
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
Topics: Aged; Antineoplastic Agents; Constipation; Disease Progression; Disease-Free Survival; Drug Administ | 2010 |
Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemokine | 2012 |
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial.
Topics: Aged; Antitussive Agents; Constipation; Cough; Dizziness; Double-Blind Method; Female; Humans; Idiop | 2012 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Prot | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Constipation; Disorders of Excessive Somnolence; Endothelial Gro | 2002 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
Thalidomide as initial therapy for early-stage myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bradycardia; Constipation; Disease Progression; Disease-Free Sur | 2003 |
[Single-agent thalidomide for advanced and refractory multiple myeloma].
Topics: Aged; Aged, 80 and over; Constipation; Disease Progression; Disorders of Excessive Somnolence; Femal | 2003 |
Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Constipation; Disease Progression; Female; Glioblastoma; Heada | 2004 |
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
Topics: Aged; Aged, 80 and over; Constipation; Disorders of Excessive Somnolence; Dose-Response Relationship | 2004 |
[Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Constipation; Cytara | 2007 |
Thalidomide as salvage therapy for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Constipation; Cyclosporine; | 1995 |
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality T | 2000 |
Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus.
Topics: Adult; Appetite; Constipation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; | 2000 |
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Topics: Adult; Affect; Aged; Angiogenesis Inhibitors; Constipation; Dizziness; Dose-Response Relationship, D | 2001 |
The treatment of advanced renal cell cancer with high-dose oral thalidomide.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Constipation; Cyt | 2001 |
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2002 |
11 other studies available for thalidomide and Constipation
| Article | Year |
|---|---|
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cycl | 2014 |
[Thalidomide-associated hypothyroidism in a patient with multiple myeloma].
Topics: Aged; Constipation; Humans; Hypothyroidism; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyro | 2015 |
Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.
Topics: Adolescent; Adult; Blood Sedimentation; China; Constipation; Dose-Response Relationship, Drug; Exant | 2016 |
[Factors affecting the response of thalidomide therapy for patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Constipation; Dexamethasone; Disease-Free Survival; Drug Eruptions; | 2010 |
Summaries for patients. Thalidomide treatment for cough in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Antitussive Agents; Constipation; Cough; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; | 2012 |
The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma.
Topics: Adult; Aged; Constipation; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Immunosuppress | 2002 |
[Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Topics: Aged; Angiogenesis Inhibitors; Antigens, CD34; Bone Marrow; Constipation; Endothelial Growth Factors | 2002 |
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Clinical Trials, Phase | 2005 |
[Potential side effects of thalidomide].
Topics: Constipation; Disorders of Excessive Somnolence; Drug Eruptions; Humans; Immunosuppressive Agents; L | 2006 |
Pneumatosis coli after thalidomide treatment.
Topics: Constipation; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Palliative Care | 2006 |
Thalidomide for the treatment of patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blood Transf | 2002 |